Literature DB >> 15557803

NMR structure of a complex between MDM2 and a small molecule inhibitor.

David C Fry1, S Donald Emerson, Stefan Palme, Binh T Vu, Chao-Min Liu, Frank Podlaski.   

Abstract

MDM2 is a regulator of cell growth processes that acts by binding to the tumor suppressor protein p53 and ultimately restraining its activity. While inactivation of p53 by mutation is commonly observed in human cancers, a substantial percentage of tumors express wild type p53. In many of these cases, MDM2 is overexpressed, and it is believed that suppression of MDM2 activity could yield therapeutic benefits. Therefore, we have been focusing on the p53-MDM2 interaction as the basis of a drug discovery program and have been able to develop a series of small molecule inhibitors. We herein report a high resolution NMR structure of a complex between the p53-binding domain of MDM2 and one of these inhibitors. The form of MDM2 utilized was an engineered hybrid between the human and Xenopus sequences, which provided a favorable combination of relevancy and stability. The inhibitor is found to bind in the same site as does a highly potent peptide fragment of p53. The inhibitor is able to successfully mimic the peptide by duplicating interactions in three subpockets normally made by amino acid sidechains, and by utilizing a scaffold that presents substituents with rigidity and spatial orientation comparable to that provided by the alpha helical backbone of the peptide. The structure also suggests opportunities for modifying the inhibitor to increase its potency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557803     DOI: 10.1023/B:JNMR.0000048856.84603.9b

Source DB:  PubMed          Journal:  J Biomol NMR        ISSN: 0925-2738            Impact factor:   2.835


  47 in total

1.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly.

Authors:  Andrew C Braisted; Johan D Oslob; Warren L Delano; Jennifer Hyde; Robert S McDowell; Nathan Waal; Chul Yu; Michelle R Arkin; Brian C Raimundo
Journal:  J Am Chem Soc       Date:  2003-04-02       Impact factor: 15.419

2.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

3.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

4.  Protein backbone angle restraints from searching a database for chemical shift and sequence homology.

Authors:  G Cornilescu; F Delaglio; A Bax
Journal:  J Biomol NMR       Date:  1999-03       Impact factor: 2.835

5.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Authors:  S M Picksley; B Vojtesek; A Sparks; D P Lane
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

6.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction.

Authors:  S Donald Emerson; Robert Palermo; Chao-Min Liu; Jefferson W Tilley; Li Chen; Waleed Danho; Vincent S Madison; David N Greeley; Grace Ju; David C Fry
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

8.  The human MDM-2 oncogene is overexpressed in leukemias.

Authors:  C E Bueso-Ramos; Y Yang; E deLeon; P McCown; S A Stass; M Albitar
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

9.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas.

Authors:  A Marchetti; F Buttitta; S Girlando; P Dalla Palma; S Pellegrini; P Fina; C Doglioni; G Bevilacqua; M Barbareschi
Journal:  J Pathol       Date:  1995-01       Impact factor: 7.996

10.  p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.

Authors:  I Shibagaki; H Tanaka; Y Shimada; T Wagata; M Ikenaga; M Imamura; K Ishizaki
Journal:  Clin Cancer Res       Date:  1995-07       Impact factor: 12.531

View more
  18 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

Review 2.  Targeting protein-protein interactions for cancer therapy.

Authors:  David C Fry; Lyubomir T Vassilev
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

3.  What induces pocket openings on protein surface patches involved in protein-protein interactions?

Authors:  Susanne Eyrisch; Volkhard Helms
Journal:  J Comput Aided Mol Des       Date:  2008-09-06       Impact factor: 3.686

4.  Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.

Authors:  Nagakumar Bharatham; Kavitha Bharatham; Anang A Shelat; Donald Bashford
Journal:  J Chem Inf Model       Date:  2014-01-21       Impact factor: 4.956

5.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

6.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

Review 7.  Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity.

Authors:  Matthew C Smith; Jason E Gestwicki
Journal:  Expert Rev Mol Med       Date:  2012-07-26       Impact factor: 5.600

8.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

9.  Monitoring Ligand-Induced Protein Ordering in Drug Discovery.

Authors:  Christy R Grace; David Ban; Jaeki Min; Anand Mayasundari; Lie Min; Kristin E Finch; Lyra Griffiths; Nagakumar Bharatham; Donald Bashford; R Kiplin Guy; Michael A Dyer; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2016-01-23       Impact factor: 5.469

10.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.